Jef Akst
Managing Editor at BioSpace
Managing Editor at @BioSpace | [email protected]
Articles
-
1 week ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong |Dan Samorodnitsky
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThis week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year’s BIO Conference in Boston. The half-team discusses this week’s biggest news: the death of another patient who took Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys.
-
1 week ago |
biospace.com | Jef Akst
For biotech companies that have come to BIO 2025 seeking partners, there’s reason for optimism. “The buy side is here in force,” Greg Benning, head of investment banking at Back Bay Life Science Advisors, said at a pre-conference satellite event Monday. Every single person BioSpace spoke with in advance of the panel said it was the partnering meetings that had brought them to the conference, which pulled to Boston more than 20,000 biopharma professionals from around the world.
-
2 weeks ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThis week the BioSpace team was sent into an after-hours scramble by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had fired the remaining members of the CDC’s Advisory Committee on Immunization Practices.
-
3 weeks ago |
biospace.com | Jef Akst |Heather McKenzie
President Donald Trump’s healthcare administrators say they are on a campaign to restore Americans’ trust in vaccines—and in the government agencies that oversee vaccine approvals and issue recommendations for their use. But the administration’s approach gives the appearance that our government leaders themselves distrust the government.
-
3 weeks ago |
biospace.com | Heather McKenzie |Jef Akst |Annalee Armstrong
> Listen on Spotify> Listen on Apple Products> Listen on Amazon Music> Listen on iHeartThe words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology’s annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech’s solid tumor bispecific BNT327.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 997
- Tweets
- 340
- DMs Open
- No
I'm looking for an editor to join our team here @biospace. If you are a journalist with an interest in the business of biopharma, let me know! https://t.co/HahZTQSVKf
FDA's Peter Marks once again from #ASGCT2024, this time on global regulatory convergence, saying that for rare diseases in particular, lack of regulatory standardization presents big challenges. @Slabodkin reporting for @BioSpace https://t.co/LCRy428ZPK #ASGCT #ASGCT24
“$4.25 million!!!” That’s the email FDA’s Peter Marks said he received from Commissioner Robert Califf when Orchard revealed the price tag of its newly approved gene therapy Lenmeldy. Check out my @biospace recap of the #ASGCT2024 fireside chat: https://t.co/PlR8mCDuxS
